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Background: Neoadjuvant chemotherapy for colorectal liver metastases (CRLM) reduces the accuracy
of liver imaging which may understage patients pre-operatively. Retrospective review of a prospective
database to determine whether liver-specific magnetic resonance imaging (MRI) prior to pre-operative
chemotherapy affects intra-hepatic recurrence and long-term outcome after hepatectomy.
Patients and methods: Between 2003 and 2009, 242 patients with CRLM underwent a hepatectomy
after 3 cycles of oxaliplatin or irinotecan-based chemotherapy. All had a liver-specific MRI immediately
pre-operatively. The outcome of patients who had a liver-specific MRI prior to chemotherapy (PCI group,
n = 92) was compared with those who did not (non-PCI group, n = 150).
Results: A liver-specific MRI pre-chemotherapy changed the staging in 56% of patients. At a median
(range) follow-up of 55 (6–94) months, there was a higher incidence of intra-hepatic recurrence at a new
site in the non-PCI group (65% vs. 48% in the PCI group, P = 0.041) and an increased rate of recurrence
in patients with the same number of lesions pre- and post-chemotherapy [hazard ratio (HR) 2.02,
1:10–3.37, P = 0.024]. The non-PCI group underwent more repeat hepatectomies than the PCI group
(24.7% vs. 13%, P = 0.034), achieving similar long-term survival.
Conclusions: A liver-specific MRI prior to chemotherapy reduces intra-hepatic recurrence and avoids a
repeat hepatectomy.
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Introduction
Colorectal cancer is common, with 39 991 new cases diagnosed in
the UK in 2008 alone.1 Of these patients, 15–20% will present with
colorectal liver metastases (CRLM)2 and a further 40–50% will
develop CRLM within 3 years of successful resection of their
primary tumour.3 Hepatic resection offers the best chance of
long-term survival, with 5-year survival rates of 37–50%.4–7
Neoadjuvant and conversion chemotherapy is increasingly being
used not only to render previously unresectable patients resect-
able8,9 but to improve overall progression-free survival.10 However,
chemotherapy can alter the image characteristics of hepatic
metastases, with some lesions undergoing cystic transformation
and others showing a complete radiological response and disap-
pearing.11 Such disappearing metastases will inevitably reappear
over time.12 Chemotherapy can also damage the background liver
parenchyma, causing steatosis, steatohepatitis or sinusoidal dila-
tation,13 with consequent alteration of the radiological character-
istics of the background liver parenchyma14,15 and less accurate
radiological detection of metastases.11
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Magnetic resonance imaging (MRI) with liver-specific contrast
agents is currently the gold standard for intra-hepatic staging of
CRLM.16,17 The aim of the present study was to compare the
outcome of patients undergoing liver resection for CRLM after
pre-operative chemotherapy who underwent liver-specific MRI
prior to starting chemotherapy (PCI group) with those patients
who were not subject to an initial liver-specific MRI (non-PCI
group). The primary objective was to compare the incidence of
intra-hepatic recurrence in both groups. Secondary outcomes
were overall survival and the incidence of re-intervention for
disease recurrence in the liver.
Materials and methods
Patient selection
A retrospective review of a prospective computer database
(Access®; Microsoft Corporation, Redmond, WA, USA), contain-
ing all liver resections for CRLM at a tertiary referral institution
from 1 June 2003 to 1 December 2009, was undertaken to identify
all those who underwent resection of CRLM after chemotherapy.
The start date coincided with the introduction of contrast-
enhanced MRI for intra-hepatic staging. The database provided
a comprehensive dataset consisting of 268 data fields compiled
contemporaneously from a standardized pro forma, which en-
compassed patient symptoms, pre-operative assessment, surgical
treatment, postoperative course, histopathology and long-term
adverse outcomes.
Pre-operative staging
All patients underwent contrast-enhanced computerized tomog-
raphy (CT) scanning of the chest, abdomen and pelvis. Patients
were defined as having synchronous metastases if they presented
with secondaries at the same time or within 3 months of their
primary tumour, even if subsequent liver resection was delayed by
chemotherapy or treatment of the primary. Liver metastases pre-
senting outside of this time frame were regarded as metachronous
or delayed. Patients with indeterminate or unfavourable factors
such as extensive lymph node involvement or T4 primary
tumours were considered for staging laparoscopy with laparo-
scopic ultrasonography. Positron emission tomography-CT (PET-
CT) was performed in an attempt to confirm or refute concerns
regarding extra-hepatic disease.
Indications for chemotherapy
Neoadjuvant or conversion chemotherapy was given either for
known resectable CRLM or to ‘downstage’ initially inoperable
CRLM, respectively. Only patients who had completed at least
three cycles of oxaliplatin or irinotecan-based regimens were
included.
MRI Protocol and patient groups
All patients underwent a liver-specific contrast-enhanced MRI
prior to surgery. Radiological assessment was undertaken using a
Symphony 1.5-T magnet (Siemens, Munich, Germany) supple-
mented by intravenous (i.v.) contrast agents and delayed phase
scans. The contrast agents used were initially Ferucarbotran
(Resovist®; Bayer Schering Pharma, Switzerland) and gadodia-
mide (Omniscan®; Amersham Health, Oslo, Norway), but since
2005, gadoxetic acid (Primovist®; Bayer Schering Pharma, Swit-
zerland) and Gadobutrol (Gadovist®; Bayer Schering Pharma,
Switzerland) have been used. The radiological protocol has been
described previously.18
The patient cohort was divided into two groups on the basis of
their imaging prior to liver resection. Patients in the pre-
chemotherapy imaging group (PCI) had a double-contrast MRI
scan of the liver prior to commencing chemotherapy (or within
the first 2 weeks) and a second similar MRI scan just prior to
surgery. Patients in the non-PCI group did not have a double-
contrast liver MRI prior to commencing chemotherapy, having
liver staging with contrast-enhanced CT or a single or non-
contrast enhanced MRI instead. All these patients had a double-
contrast MRI prior to surgery.
Many patients were referred from other institutions. If they
were referred prior to commencing chemotherapy, liver-specific
imaging was undertaken at Basingstoke using our MRI protocol.
Otherwise pre-chemotherapy imaging was obtained from the
referring unit. Since March 2006, all radiology has been down-
loaded onto an intranet imaging database (Centricity Enterprise
Web V3.0; GE Medical systems, 1995–2006, Chalfont St Giles,
Buckinghamshire, UK). Prior to this date, hard copy films were
obtained. An assessment of the quality of all MRI scans from
referring centres was undertaken independently, by two hepato-
biliary surgeons (M.R. and F.W.), to allow final group allocation.
MRI scans with single or no contrast agents were deemed inad-
equate and these patients were placed in the non-PCI group.
Details of the radiological CRLM distribution both pre- and
post-chemotherapy were documented. In addition, those patients
in the PCI group had their response to chemotherapy assessed
according to the response evaluation criteria in solid tumours
(RECIST) criteria.19
Liver surgery
Fitness for liver surgery was assumed by survival from a colorectal
resection and/or a willingness to proceed regardless of age. Resec-
tability for cure in all patients required complete resection of all
liver metastases, regardless of size, number, distribution or width
of resection margin, while preserving a sufficient volume of func-
tioning liver parenchyma (usually greater than 25–30% of normal
liver parenchymal volume as estimated by MRI20). It is our phi-
losophy to resect all known sites of disease seen on the original
scans. All patients undergo intra-operative ultrasound (IOUS) at
the time of resection. For lesions that have undergone a complete
radiological response an intensive search using palpation and
IOUS is made. If the area can be removed by an anatomical
segmental resection leaving a viable volume of functioning liver
this is performed. However, on occasions when a blind resection
would endanger key biliary/vascular structures or leave an insuf-
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ficient volume of residual liver, we have elected to closely observe
the site of disease and treat any recurrence when it occurs.
The anaesthetic and surgical techniques specific to both
primary and repeat hepatic resection have been described in detail
previously.20–22 The nomenclature and extent of hepatic resection
were recorded according to the terminology defined by Couinaud
and, more recently, the Terminology Committee of the Interna-
tional Hepato-Pancreato-Biliary Association.23 A major resection
was defined as a resection of three or more segments.
Post-operative follow-up
Every patient underwent 6-monthly measurement of serum car-
cinoembryonic antigen (CEA) and CT scanning of the chest,
abdomen and pelvis for 3 years, then annually for 10 years. A
colonoscopy was performed at 2 years. If recurrent disease
occurred, assessment for repeat resection was undertaken. Up-to-
date survival and disease status were confirmed on a 6-monthly
telephone audit by database staff. No patient was lost to follow-up.
Outcome measures
The primary outcome measure was the incidence of and time to
intra-hepatic recurrence. Secondary outcomes included disease-
free and overall survival and the need for repeat liver resection. All
outcome measures were taken from the time of the first liver
resection.
Exclusions
The patient flow chart and summary of exclusions are presented
in Fig. 1 and Table 1. Pre-operative chemotherapy had to be of
sufficient potency and duration to elicit a significant effect on the
CRLM. Hence, patients had to have completed three or more
cycles of oxaliplatin or irinotecan-based chemotherapy. Sub-
optimal regimens such as 5-fluorouracil (5-FU) monotherapy or
regimens of a shorter duration were excluded. The CRLM had to
have been diagnosed and staged either prior to commencement of
chemotherapy or before the second cycle. This meant those with
CRLM diagnosed during or immediately after adjuvant chemo-
therapy for their primary were excluded along with those who
developed CRLM sometime after adjuvant therapy and then
proceeded directly to liver resection without further treatment.
Patients who were inoperable at the time of resection or those
that progressed after the first stage of a two-stage hepatectomy
were excluded. Four patients with inoperable, large volume
disease (>10 CRLM) before chemotherapy were also excluded
(two in each group). These patients had exceptional responses to
chemotherapy and underwent liver resection after a trial of time,
to clear all identifiable sites of disease, knowingly leaving sites of
disappearing metastases. Three out of the four patients also
underwent concomitant intra-operative ablation. The in-situ dis-
appearing lesions were closely observed. As expected, all patients
have had early intra-hepatic recurrence and have undergone
subsequent resection or ablation.
Statistical analysis
Continuous variables are presented as median (with range) and
categorical data presented as frequency and percentages. The
Mann–Whitney U-test for continuous data and either Pearson’s
chi-square test or Fisher’s exact test for categorical data was used
to detect differences between the two group cohorts. Kaplan–
Meier curves were plotted to determine the time to hepatic recur-
rence and survival outcomes and expressed in median and 95%
confidence interval. Statistical significance was analysed with the
log-rank (Mantel–Cox) test. The Cox proportional-hazard regres-
sion analysis was used to analyse the hazard ratio (HR) of the
survival distribution to the variables. A P-value of less than 0.05
was considered significant. Data were analysed using SPSS
software (version 19.0) (IBM SPSS Inc., Chicago, IL, USA).
Results
During the study period, 818 liver resections were undertaken in
715 patients for CRLM with a curative intent. Of these, 242
patients met the study inclusion criteria (Fig. 1).
Patient demographics and tumour characteristics
The demographic and clinicopathological characteristics of the
242 patients are summarized in Table 2. The two groups were
similar with respect to age, gender, nodal status of their primary
tumour and pre-chemotherapy CEA. The PCI group had a
significantly higher median (range) number of CRLM seen on
imaging prior to chemotherapy [3 (1–14)] compared with the
non-PCI group [2 (1–20], that was no longer significant after
chemotherapy. The median (range) size of the largest CRLM pre-
chemotherapy was 33 (5–200) mm in the PCI group, similar to
that in the non-PCI group [30 (4–130) mm, P = 0.545]. Concomi-
tant extrahepatic disease was present in 38 patients (16%) and
there was no difference between groups. The median (range)
follow-up for these 240 patients was 55 (6–94) months.
Comparison of referral radiology to liver-specific MRI
The modality and quality of pre-chemotherapy imaging is shown
in Table 3. The majority of patients in both groups were referred
with a CT with i.v. contrast. Twenty patients in the PCI group had
a good quality MRI scan performed at the referring centre,
compared with none in the non-PCI group.
In the PCI group, three patients were referred directly for a
detailed liver MRI scan without a baseline CT scan and 2 of the 20
patients presenting with good quality liver MRIs did not have
their CT images available. The referring imaging of a further three
patients was incomplete. Thus a comparison of a good quality
liver MRI scan to CT scan or poor quality liver MRI scan was
possible in 84 of 92 patients. Of these 84 patients, the liver-specific
MRI scan identified an additional 109 CRLMs in 39 (46%)
patients. Of these 109 additional metastases, 96 were not seen on
previous liver imaging and the remaining 13 lesions had been
incorrectly regarded as indeterminate. The median (range) size of
300 HPB
HPB 2012, 14, 298–309 © 2012 International Hepato-Pancreato-Biliary Association
818 resections for CRLM in 715 patients
1 June 2003 to 1 Dec 2009
296 patients
no pre-operative
chemotherapy
7
first resection prior to
series or elsewhere
8
no MRI
155
sub-optimal
chemotherapy
419 patients
pre-operative
chemotherapy
257
optimal pre-operative
chemotherapy
249
MRI prior to surgery
PCI = 94
paired MRI pre and post-
chemotherapy
2
unresectable at surgery or
progressed
5
unresectable at surgery or
progressed
PCI group = 92
final cohort
 Non PCI group = 150
final cohort
non PCI = 155
no detailed MRI before
chemotherapy
Figure 1 Patient flow chart
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the newly diagnosed CRLM was 8 (4–30) mm. In addition, the
liver-specific MRI confirmed the benign nature of 12 indetermi-
nate lesions in a further 9 patients. Overall a good quality liver-
specific MRI prior to commencing chemotherapy changed the
intra-hepatic staging in 47 of 84 (56%) patients.
The median (range) time interval between scans was 6 (0–54)
weeks. Those with longer intervals often had treatment of their
primary between imaging. In the two patients with the longest
intervals (24 and 54 weeks), re-staging was delayed by post-
operative complications after the primary surgery.
Chemotherapy regimens and response
Details of the chemotherapy regimens are shown in Table 4. The
majority of patients [n = 219 (90%)] received oxaliplatin-based
chemotherapy. Thirty-one (17%) patients were treated with oxali-
platin or irinotecan plus monoclonal antibodies, with no signifi-
cant difference between the groups. The median (range) number
of cycles was six (3–24) and the median (range) time interval
between cessation of chemotherapy and liver surgery was 8
(4–99) weeks. Although the median number of cycles was the
same between the two groups, the PCI group contained signifi-
cantly more patients who received just 3–4 cycles of chemotherapy
before surgery (37% vs. 19%, P = 0.003).
The radiological response to chemotherapy in the liver could
be accurately assessed using RECIST criteria19 for patients in the
PCI group, who had paired MRI scans. Eleven patients (12%)
progressed, 17 (18%) remained stable, 61 (66%) had a partial
response and 3 (3%) had a complete radiological response.
The change in number of CRLM seen on pre- and post-
chemotherapy imaging is detailed in Table 4. This shows that
the majority of patients [137 (57%)] had the same number of
metastases. Thirty-five (14%) patients developed new lesions,
with twice as many in the non-PCI group (18%) compared with
the PCI group (9%). This just failed to reach statistical significance
(P = 0.059). Seventy patients (29%) had at least one lesion disap-
pear with chemotherapy. Of this last group, a total of 272
metastases underwent a complete radiological response to chemo-
therapy. These patients were more likely to have >3 metastases
prior to commencing chemotherapy (54%), compared with those
whose numbers of metastases remained unchanged (14%) or
increased after chemotherapy (32%) P = 0.001.
Liver surgery and post-operative course
The details of the liver surgery and post-operative course are
shown in Table 5. The majority of patients underwent a major
liver resection. There was no difference in median blood loss, R0
resection rate, morbidity or mortality between groups. There was
one post-operative death in the non-PCI group, 4 weeks after
surgery, as a result of pneumonia. The only significant difference
between the groups was that more patients in the PCI group
required a two-staged liver resection [n = 7 (8%)] compared with
the non-PCI group [n = 2 (1%), P = 0.029].
Disease recurrence
The sites of intra-hepatic recurrence are shown in Table 6. There
was no difference in the recurrence rates at the surgical margin but
significantly more patients in the non-PCI group developed intra-
hepatic recurrence at new sites (65% vs. 48%, P = 0.041). More
patients in the PCI group developed recurrence at sites of disap-
pearing metastases compared with the non-PCI group (16% vs.
3%, P = 0.005).
The rate of intra-hepatic recurrence over time is shown in
Fig. 2. While patients in the PCI group had a lower recurrence rate
compared with those in the non-PCI group, this failed to reach
statistical significance (P = 0.1, log rank test). When the rate of
intra-hepatic recurrence was analysed according to the radiologi-
cal response to chemotherapy, a significant risk stratification was
observed. Patients with the same number of CRLM pre- and post-
chemotherapy had a significantly reduced risk of liver recurrence
compared with those patients whose had at least one lesion dis-
appear with chemotherapy (HR 1.51, P = 0.014) or those patients
who developed additional CRLM on the post-chemotherapy MRI
scan (Hazard ratio 2.03, P = 0.007) (Fig. 3). A sub-group analysis
within each group demonstrated similar stratification of out-
comes (Fig. 4a–b). When only those patients with the same
number of CRLM pre- and post-chemotherapy are analysed, a
significant increase in intra-hepatic recurrence is seen for patients
in the non-PCI group [HR = 2.02, 95% confidence interval (CI)
1.10–3.73, P = 0.024] (Fig. 5).
Table 1 Details of excluded patients
Reason for exclusion Number of
patients
Chemotherapy 155
Agent (sub-optimal) 82
Duration (<3 cycles) 55
Timing (no chemotherapy between
diagnosis and surgery)
CRLM detected during chemotherapy 4
Immediately after 4
>12 months after completion 10
No MRI 8
Metal 1
Claustrophobia 3
Unknown 4
Surgical 14
First resection before series or elsewhere 7
Progressive disease after 1st stage liver resection 2
>10 CRLM, known missing lesions (see text) 4
Irresectable at operation 1
CRLM, colorectal liver metastases; MRI, magnetic resonance imaging.
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Clinical impact of recurrent disease
Forty-eight patients underwent 54 repeat liver resections with an
additional 12 episodes of CRLM ablation (either radiofrequency
or microwave) for recurrent disease. One other patient underwent
an attempted repeat liver resection (included in the 12 patients in
the PCI group on an intention-to-treat basis). Significantly more
patients in the non-PCI group required at least one repeat liver
resection (n = 37/150, 24.7%) compared with those in the PCI
group (n = 12/92, 13%, P = 0.034). Two patients out of the 48
(both in the non-PCI group) died within 90 days of their repeat
liver resection (3.7% mortality). One patient died of a post-
operative myocardial infarction on the first day after his fourth
liver resection, 41 months after his first liver resection and the
other patient died of a pulmonary embolus 82 days after her
second liver resection, 19 months after her first. Significant but
non-life-threatening morbidity was seen in a further 11 (22%)
patients.
Survival
To date, 64 patients remain recurrence free. In addition, 38
patients are disease free after at least one re-resection and/or abla-
tion. Thus, 102 out of 242 patients (42%) are disease free to date.
The median (95% CI) survival for the entire cohort was 42.1
(31.6–52.3) months. There was no statistical difference between
the two groups for survival (Fig. 6). However, when overall sur-
vival for the entire patient cohort was analysed by response to
chemotherapy, the patients who had lesions, which disappeared,
did significantly better than either those patients in whom the
numbers of metastases remained unchanged, or those patients
who developed additional metastases after chemotherapy
(median survival 57.7 vs. 50.3 vs. 28.0 months, respectively,
Table 2 Patient demographics and tumour characteristics
Variable Total
(range or %)
PCI group
(range or %)
Non-PCI group
(range or %)
P-value
Gender
Male 160 (66) 61 (66) 99 (66) 1.0**
Female 82 (34) 31 (34) 51 (34)
Age (median years) 63 (30–85) 63 (30–79) 63 (30–85) 0.327*
Primary tumour
Node positive 172 (71) 62 (67) 110 (73) 0.084**
Missing data 5 (2) 3 (3) 2 (1)
CEA median 4 (0–1679) 4 (0.5–820) 4 (0–1679) 0.890*
CRLM
Time from diagnosis of primary
<3 months 183 (75) 67 (73) 116 (77) 0.067**
3 to 12 months 16 (7) 3 (3) 13 (9) 0.100***
>12 months 43 (18) 22 (24) 21 (14) 0.033**
CRLM number
Pre-chemo median 2 (1–20) 3 (1–14) 2 (1–20) 0.033*
Post-chemo median 2 (0–14) 2 (0–14) 2 (0–14) 0.208*
3 171 (71) 57 (62) 114 (75) 0.019**
Size of the largest CRLM
Pre-chemo median (mm) 30 (4–200) 33 (5–200) 30 (4–130) 0.545*
Post-chemo median (mm) 23 (0-120) 23(0–120) 21 (0–120) 0.302*
<50 mm 182 (75) 71 (77) 111 (74) 0.577**
50 mm or more 60 (25) 21 (23) 39 (26)
EHD at time of diagnosis 38 (16) 14 (15) 24 (16) 0.862**
*Mann-Whitney U test; **Pearson's chi-square test and *** Fisher's exact test.
CEA, carcinoembryonic antigen; CRLM, colorectal liver metastases; EHD, extra hepatic disease.
Table 3 Pre-chemotherapy referral radiology
Referring imaging
modality
PCI n = 92 Non-PCI
n = 150
Liver ultrasound 2 0
CT with i.v. contrast 89 (84 available for comparison) 149
Liver-specific MRI
Poor quality 2 31
Good quality 20 0
PCI, pre-chemotherapy imaging; CT, computed tomography;
i.v., intravenous; MRI, magnetic resonance imaging.
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P < 0.001). This last group with progressive disease on chemo-
therapy had the worst prognosis (HR = 2.35, 95% CI 1.48–3.71,
P = 0.001) (Fig. 7).
Discussion
The present study underlines the importance of obtaining a
detailed liver-specific MRI scan before the commencement of che-
motherapy. Not only did a detailed MRI change the intra-hepatic
staging in 56% of patients with CRLM, it was associated with a
reduced incidence of new lesions within the liver after hepatic
resection. Patients denied such detailed pre-chemotherapy
imaging underwent a higher number of repeat liver resections to
achieve a similar long-term outcome. Repeat liver resections for
recurrent CRLM are more technically challenging and submit the
patient to additional mortality and morbidity.24,25 A detailed liver-
specific MRI before chemotherapy could avoid this.
The logical explanation for these results is that lesions that
would have been detected by a liver-specific MRI had undergone
a complete radiological response (CRR) during the neoadjuvant
chemotherapy and were therefore not detected on the subsequent
pre-operative MRI. Any lesion outside the planned resection has a
Table 4 Chemotherapy details
Total n (%) PCI n (%) Non-PCI n (%) P-value
Chemotherapy
Indication
Down staging 85 (35%) 37 (40%) 48 (32%) 0.231**
Neoadjuvant 157 (65%) 55 (60%) 102 (68%)
Agent
Oxaliplatin based 219 (90%) 85 (92%) 134 (89%) 0.431**
Irinotecan based 23 (10%) 7 (8%) 16 (11%)
Monoclonal antibodies 31 (17%) 15 (16%) 16 (11%)
Median (range) no of cycles 6 (3–24) 6 (3-12) 6 (3–24) 0.006*
No. of patients receiving 3–4 cycles 62 (26%) 34 (37%) 28 (19%) 0.003**
Change in no of CRLM after chemotherapy
No change 137 (57%) 56 (61%) 81 (54%) 0.350**
Increase 35 (14%) 8 (9%) 27 (18%) 0.059**
Decrease 70 (29%) 28 (30%) 42 (28%) 0.770**
*Mann–Whitney U-test; **Pearson's chi-square test.
CRLM, colorectal liver metastases.
Table 5 Liver surgery and post-operative course
Variable Total n (%) PCI n (%) Non-PCI n (%) P-value
Surgery
Major resection 159 (66) 62 (67) 97 (65) 0.639**
Minor resection 83 (34) 30 (33) 53 (35)
Median (range) blood loss/mL 350 (30–5344) 380 (40–1950) 358 (30–5344) 0.511*
Mortality (90 days) 1 (0.4) 0 1 (0.6) –
Morbidity 61 (25) 18 (20) 43 (29) 0.787**
Minor 54 (22) 17 (18) 37 (25) 0.261**
Major 7 (3) 1 (2) 6 (4) 0.257***
Resection margin
Involved 33 (14) 14 (15) 19 (13) 0.571**
<1 mm 24 (9) 10 (11) 14 (9) 0.823**
1–4 mm 62 (26) 25 (27) 37 (25) 0.648**
5–9 mm 44 (18) 16 (18) 28 (19) 0.806**
>10 mm 75 (31) 26 (28) 49 (32) 0.571**
No lesion seen at pathology 4 (2) 1 (1) 3 (2) –
*Mann-Whitney U-test; **Pearson's chi-square test; ***Fisher's exact test.
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high chance of being undetected at the time of surgery (even by
intra-operative ultrasound) and left in situ, predisposing to an
early liver recurrence.12,26,27
Predictors of a patient with CRLM having at least one metasta-
sis that disappears include small size of CRLM (<3 cm), a partial
or complete response to chemotherapy,12 multiple (>3) CRLM
and longer duration of chemotherapy.27 In the present study, the
median size of additional CRLM detected by MRI was 8 mm
(range 4–30 mm), and over two-thirds of patients had a signifi-
cant response to chemotherapy. This is at the upper end of
reported response rates for neoadjuvant CRLM chemotherapy28
and reflects the inclusion of only oxaliplatin or irinotecan-based
regimes, with at least three cycles successfully delivered. Given the
high response rate and small size of additional CRLM seen on
the pre-chemotherapy liver MRI, it is likely many patients in
the inadequately-imaged group would have come to surgery with
unrecognized metastases. The crucial question becomes whether
knowledge of these sites alters disease outcome.
When time to liver recurrence is plotted on a Kaplan–Meier
curve, a stable observable difference in hepatic recurrence-free
survival is seen, but significance is not reached (P = 0.100) (Fig. 2).
However, a significant stratification of recurrence risk is seen
when the change in number of CRLM during chemotherapy is
analysed (Fig. 3). Those with the same number of CRLM pre- and
post-chemotherapy have the least risk of liver recurrence com-
pared with those with fewer or extra lesions. Patients with extra
metastases in the adequately imaged group will by definition have
progressive disease19 and be at a greater risk of early intrahepatic
recurrence.29 For the inadequately imaged group, additional
lesions seen on the post-chemotherapy MRI will have either pro-
gressive disease or metastases missed on the initial imaging which
are now seen on the liver-specific MRI. This group does contain
more patients with extra metastases after chemotherapy, but this
just fails to reach significance (18% vs. 9%; P = 0.059).
Table 6 Site of any intra-hepatic recurrence
Site of liver recurrence PCI n (%) Non PCI n (%) P-value
Surgical margin 13 (30) 23 (23) 0.371*
New site 21 (48) 63 (65) 0.041*
Site of disappearing metastasis not resected 7 (16) 3 (3) 0.005**
Unknown 3 (6) 8 (9) 1**
*Pearson's-chi square test; **Fisher's exact test.
PCI, pre-chemotherapy imaging.
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Figure 4 (a) Kaplan–Meier plot to show intra-hepatic recurrence-free
survival according to number of colorectal liver metastases (CRLM)
before and after chemotherapy in the pre-chemotherapy imaging
(PCI) group. (b) Kaplan–Meier plot to show intra-hepatic recurrence-
free survival according to number of CRLM before and after chemo-
therapy for the non-PCI group
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Figure 5 Kaplan–Meier plot to show the intra-hepatic recurrence-
free survival in patients with same number of colorectal liver
metastases (CRLM) pre- and post-chemotherapy according to
patient groups [pre-chemotherapy imaging (PCI) and non-PCI)
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Figure 6 Kaplan–Meier survival plot of overall survival for pre-
chemotherapy imaging (PCI) and non-PCI groups
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Those with known disappearing lesions during chemotherapy
are expected to have a favourable overall outcome after CRLM
resection, as they are chemo-responsive.28 However, the rate of
liver recurrence in these patients is higher than in those with the
same number of metastases. It is our philosophy to try to resect all
original sites of metastatic disease. However, a metastasis that is no
longer detectable on MRI or intra-operatively will often require a
localized segmental or wedge resection that is difficult to perform
without endangering key hepatic vascular or biliary structures.
Furthermore, a blind resection cannot guarantee a clear margin
and on occasion we have left such lesions in situ and followed
them closely with serial imaging, aiming for a repeat resection if
and when they recur. This may explain why, despite the favourable
response to chemotherapy, the patients with disappearing lesions
have a higher rate of liver recurrence (HR = 1.51 95% CI 1.1–2.27,
P = 0.014) than those with the same number. Van Vledder and
colleagues similarly demonstrated that patients with unresected
metastases that disappeared have higher rates of intrahepatic
recurrence.27
The present findings give further indirect evidence that
metastases that disappear with chemotherapy do recur and that
every effort should be made to identify and resect them. Benoist
and co-workers12 reported the recurrence of CRLM at the site of
unresected disappearing lesions in 23 of 31 (74%) lesions after
1 year of follow-up. Tanaka and co-workers26 reported similar
findings, with in situ recurrence of lesions which disappeared, in
11 of 27 (41%) lesions, at a median of 14 months follow-up. Both
series identified a residual tumour in 60–80% of patients that were
resected. Other workers have found a better correlation of com-
plete radiological response (CRR) with a complete pathological
response (CPR) but still report recurrence in 27–38% of
patients.30
An argument in favour of administering chemotherapy before
liver resection is that this allows an assessment of the tumour
biology. Rather than the radiological response to chemotherapy,
the pathological response is emerging as the most accurate and
important prognostic indicator.31 Several authors have found a
strong correlation with the degree of pathological response and
outcome.26,31,32 Those with a CPR have the best outcomes and yet
a CRR only poorly correlates with a CPR. As many lesions that
have undergone a CPR are still visible on imaging and residual
viable tumour can be found in 60% to 80% of lesions which have
a CRR that are resected.12,26 In our cohort, 11 out of 242 patients
(4.5%) had a CPR in all lesions on histology. Yet only one of these
had a CRR during chemotherapy. Similarly, Tanaka et al. found
58% of lesions with CPR occurred in CRLM still seen on a pre-
operative CT imaging26 and concluded that no modern imaging
technique, even PET-CT, can reliably predict CPR and therefore,
assessment of CPR ultimately depends on histopathological
examination. It appears that the pathological response occurs
early in systemic treatment. Ribero and colleagues, using a
regimen of 5FU, Oxaliplatin (FOLFOX) and Bevacizumab,
showed that only two to four cycles is required for CPR and that
the addition of more chemotherapy had no additional response.33
In contrast, CRLM are more likely to exhibit a radiological
response and disappear with longer durations of chemotherapy.27
Our patients received a median number of 6 (range, 3–24) cycles
of chemotherapy before surgery. This was in spite of the majority
(65%) receiving their chemotherapy in the setting of known
resectable CRLM. Interestingly, those with more detailed imaging
were more likely to receive only three to four cycles of pre-
operative chemotherapy. These patients were often referred before
starting their systemic treatment and it is possible that referral to
a hepatobiliary surgeon results in a lesser amount of pre-operative
chemotherapy or certainly earlier re-staging because of concerns
regarding hepatoxicity and disappearing lesions. In addition, there
is a group of patients in whom the CRLM remains just visible on
the pre-operative MRI but are not seen or palpable at the time of
surgery owing to severe steatosis and small size. These patients are
as difficult to manage. While some have advocated the placement
of radiological placed coils next to lesions at risk of disappearing,34
we worry about the associated morbidity and theoretical risk of
tumour seeding.35 Thus we advocate limiting preoperative chemo-
therapy to the two to four cycles needed to elicit a pathological
response before performing surgery in the case of resectable
CRLM, or re-staging in the case of conversion chemotherapy.
It may be preferable to avoid pre-operative chemotherapy
altogether, in the cases of small isolated CRLM (<3 cm).
While the strength of the present study is the large number of
patients undergoing a potent, modern chemotherapy regime
with radiological and clinical outcomes collected on a robust
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Figure 7 Kaplan–Meier plot shows overall survival for the entire
cohort according to the radiological response to chemotherapy
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prospective database, the study design is still retrospective and has
several limitations. First, this is a selected population containing
only 34% (242 of 715) of all patients undergoing a liver resection
for CRLM at our institution over the study period. In all, 41% did
not receive any pre-operative chemotherapy and another 37%
received what we have called a sub optimal pre-operative chemo-
therapy regime. Not surprisingly our cohort therefore contains a
high incidence of CRLM that disappear during treatment that
would lend itself to the study’s hypotheses. But as pre-operative
chemotherapy becomes increasingly used and Oxaliplatin- and
Irinotecan-based regimes are now the standard of care in the
first-line systemic treatment of CRLM36 we feel this makes
the present study population, and the outcomes, increasingly
pertinent.
We also acknowledge that this is not a formal diagnostic com-
parison of imaging modalities. This was never the aim of the
present study as we set out to study the clinical outcome of omit-
ting a detailed pre-chemotherapy MRI scan. What is clear is that a
detailed liver MRI alters the liver staging of over half the patients
before chemotherapy is started. Finally the retrospective design
has meant that it was not possible to accurately identify how many
known CRLM that disappeared were able to be detected at the
time of surgery nor to accurately identify all patients who had
such lesions left in situ.
Conclusion
We have shown that a detailed high-quality MRI assessment of
CRLM before pre-operative chemotherapy changed the intra-
hepatic lesion detection in 56% of patients. Patients denied
adequate pre-chemotherapy radiological staging underwent a
significantly higher re-intervention with surgery and/or ablation
to achieve a similar outcome. We would urge all Oncologists
to obtain a liver-specific MRI where possible before starting
chemotherapy.
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